Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease
10.1038/sj.mp.4001854
Crossref journal-article
Springer Science and Business Media LLC
Molecular Psychiatry (297)
Bibliography

Martins, I. J., Hone, E., Foster, J. K., Sünram-Lea, S. I., Gnjec, A., Fuller, S. J., Nolan, D., Gandy, S. E., & Martins, R. N. (2006). Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s disease and cardiovascular disease. Molecular Psychiatry, 11(8), 721–736.

Authors 9
  1. I J Martins (first)
  2. E Hone (additional)
  3. J K Foster (additional)
  4. S I Sünram-Lea (additional)
  5. A Gnjec (additional)
  6. S J Fuller (additional)
  7. D Nolan (additional)
  8. S E Gandy (additional)
  9. R N Martins (additional)
References 236 Referenced 284
  1. Post SG . Future scenarios for the prevention and delay of Alzheimer disease onset in high-risk groups. An ethical perspective. Am J Prev Med 1999; 16: 105–110. (10.1016/S0749-3797(98)00139-1) / Am J Prev Med by SG Post (1999)
  2. Aged and Community Care Division. Department of Health & Family Services: Canberra, 1998 p. 81.
  3. Arias E, Smith BL . Deaths: preliminary data for 2001. Natl Vital Stat Rep 2003; 51: 1–44. / Natl Vital Stat Rep by E Arias (2003)
  4. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989; 262: 2551–2556. (10.1001/jama.1989.03430180093036) / JAMA by DA Evans (1989)
  5. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM . Clinical diagnosis of Alzheimer's disease. Neurology 1984; 34: 939–944. (10.1212/WNL.34.7.939) / Neurology by G McKhann (1984)
  6. Mega MS, Cummings JL, Fiorello T, Gornbein J . The spectrum of behavioural changes in Alzheimer's disease. Neurology 1996; 46: 130–135. (10.1212/WNL.46.1.130) / Neurology by MS Mega (1996)
  7. Gilman S . Alzheimer's disease. Perspect Biol Med 1997; 40: 230–245. (10.1353/pbm.1997.0020) / Perspect Biol Med by S Gilman (1997)
  8. Rubinsztein DC . The genetics of Alzheimer's disease. Prog Neurobiol 1997; 52: 447–454. (10.1016/S0301-0082(97)00014-2) / Prog Neurobiol by DC Rubinsztein (1997)
  9. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 1992; 360: 672–674. (10.1038/360672a0) / Nature by M Citron (1992)
  10. Van Broeckhoven C, Backhovens H, Cruts M, De Winter G, Bruyland M, Cras P et al. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3. Nat Genet 1992; 2: 335–339. (10.1038/ng1292-335) / Nat Genet by C Van Broeckhoven (1992)
  11. Sherrington R, Froelich S, Sorbi S, Campion D, Chi H, Rogaeva EA et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 1996; 5: 985–988. (10.1093/hmg/5.7.985) / Hum Mol Genet by R Sherrington (1996)
  12. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754–760. (10.1038/375754a0) / Nature by R Sherrington (1995)
  13. Kwok JB, Taddei K, Hallupp M, Fisher C, Brooks WS, Broe GA et al. Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype. NeuroReport 1997; 8: 1537–1542. (10.1097/00001756-199704140-00043) / NeuroReport by JB Kwok (1997)
  14. Taddei K, Kwok JB, Kril JJ, Halliday GM, Creasey H, Hallupp M et al. Two novel presenilin-1 mutations (Ser169Leu and Pro436Gln) associated with very early onset Alzheimer's disease. NeuroReport 1998; 9: 3335–3339. (10.1097/00001756-199810050-00034) / NeuroReport by K Taddei (1998)
  15. Lendon CL, Ashall F, Goate AM . Exploring the etiology of Alzheimer disease using molecular genetics. JAMA 1997; 277: 825–831. (10.1001/jama.1997.03540340059034) / JAMA by CL Lendon (1997)
  16. Rocca WA, Amaducci LA, Schoenberg BS . Epidemiology of clinically diagnosed Alzheimer's disease. Ann Neurol 1986; 19: 415–424. (10.1002/ana.410190502) / Ann Neurol by WA Rocca (1986)
  17. Sparks DL, Hunsaker JC, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR . Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 1990; 11: 601–607. (10.1016/0197-4580(90)90024-T) / Neurobiol Aging by DL Sparks (1990)
  18. Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB . Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord 2003; 27: 260–268. (10.1038/sj.ijo.802225) / Int J Obes Relat Metab Disord by MF Elias (2003)
  19. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I . An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 2003; 163: 1524–1528. (10.1001/archinte.163.13.1524) / Arch Intern Med by D Gustafson (2003)
  20. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R . Diabetes mellitus and the risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154: 635–641. (10.1093/aje/154.7.635) / Am J Epidemiol by JA Luchsinger (2001)
  21. Stewart R, Liolitsa D . Type 2 diabetes, cognitive impairment and dementia. Diabet Med 1999; 16: 93–112. (10.1046/j.1464-5491.1999.00027.x) / Diabet Med by R Stewart (1999)
  22. Sanchez L, Alvarez V, Gonzalez P, Gonzalez I, Alvarez R, Coto E . Variation in the LRP-associated protein gene (LRPAP1) is associated with late onset Alzheimer disease. Am J Med Genet 2001; 105: 76–78. (10.1002/1096-8628(20010108)105:1<76::AID-AJMG1066>3.0.CO;2-R) / Am J Med Genet by L Sanchez (2001)
  23. Kamboh MI, Ferrell RE, Dekosky ST . Genetic association studies between Alzheimer's disease and two polymorphisms in the low density lipoprotein receptor related protein gene. Neurosci Lett 1998; 244: 65–68. (10.1016/S0304-3940(98)00141-4) / Neurosci Lett by MI Kamboh (1998)
  24. Hatanaka Y, Kamino K, Fukuo K, Mitsuda N, Nishiwaki-Ueda Y, Sato N et al. Low density lipoprotein receptor-related protein gene polymorphisms and risk for late-onset Alzheimer's disease in a Japanese population. Clin Genet 2000; 58: 319–323. (10.1034/j.1399-0004.2000.580410.x) / Clin Genet by Y Hatanaka (2000)
  25. Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 2000; 55: 1158–1166. (10.1212/WNL.55.8.1158) / Neurology by BL Plassman (2000)
  26. Jellinger KA . Traumatic brain injury as a risk factor for Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75: 511–512. / J Neurol Neurosurg Psychiatry by KA Jellinger (2004)
  27. Buckwalter JG, Sobel E, Dunn ME, Diz MM, Henderson VW . Gender differences on a brief measure of cognitive functioning in Alzheimer's disease. Arch Neurol 1993; 50: 757–760. (10.1001/archneur.1993.00540070069018) / Arch Neurol by JG Buckwalter (1993)
  28. Zhang MY, Katzman R, Salmon D, Jin H, Cai GJ, Wang ZY et al. The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education. Ann Neurol 1990; 27: 428–437. (10.1002/ana.410270412) / Ann Neurol by MY Zhang (1990)
  29. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K . Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985; 82: 4245–4249. (10.1073/pnas.82.12.4245) / Proc Natl Acad Sci USA by CL Masters (1985)
  30. Glenner GG, Wong CW . Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Comm 1984; 120: 885–890. (10.1016/S0006-291X(84)80190-4) / Biochem Biophys Res Comm by GG Glenner (1984)
  31. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733–736. (10.1038/325733a0) / Nature by J Kang (1987)
  32. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992; 258: 126–129. (10.1126/science.1439760) / Science by M Shoji (1992)
  33. Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ . Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 1992; 357: 500–503. (10.1038/357500a0) / Nature by C Haass (1992)
  34. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735–741. (10.1126/science.286.5440.735) / Science by R Vassar (1999)
  35. Kimberley WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ . Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci USA 2003; 100: 6382–6387. (10.1073/pnas.1037392100) / Proc Natl Acad Sci USA by WT Kimberley (2003)
  36. Soriano S, Chyung AS, Chen X, Stokin GB, Lee VM, Koo EH . Expression of beta amyloid precursor protein-CD3 gamma chimeras to demonstrate the selective generation of amyloid beta (1–40) and amyloid beta (1–42) peptides within secretory and endocytic compartments. J Biol Chem 1999; 274: 32295–32300. (10.1074/jbc.274.45.32295) / J Biol Chem by S Soriano (1999)
  37. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46 (6): 860–866. (10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M) / Ann Neurol by CA McLean (1999)
  38. Miklossy J, Taddei K, Martins R, Escher G, Kraftsik R, Pillevuit O et al. Alzheimer disease: curly fibers and tangles in organs other than brain. J Neuropathol Exp Neurol 1999; 58: 803–814. (10.1097/00005072-199908000-00003) / J Neuropathol Exp Neurol by J Miklossy (1999)
  39. Sparks DL, Martin TA, Gross DR, Hunsaker JC . Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc Res Tech 2000; 50: 287–290. (10.1002/1097-0029(20000815)50:4<287::AID-JEMT7>3.0.CO;2-L) / Microsc Res Tech by DL Sparks (2000)
  40. Honig LS, Kukull W, Mayeux R . Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 2005; 64: 494–500. (10.1212/01.WNL.0000150886.50187.30) / Neurology by LS Honig (2005)
  41. Grant WB . Dietary links to Alzheimer's disease. Alz Dis Rev 1997; 2: 42–55. / Alz Dis Rev by WB Grant (1997)
  42. Roher AE, Kuo YM, Kokjohn KM, Emmerling MR, Gracon S . Amyloid and lipids in the pathology of Alzheimer's disease. Amyloid 1999; 6: 136–145. (10.3109/13506129909007315) / Amyloid by AE Roher (1999)
  43. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D et al. Elevated low density lipoprotein in Alzheimer's disease correlates with brain abeta1–42 levels. Biochem Biophys Res Comm 1998; 252: 711–715. (10.1006/bbrc.1998.9652) / Biochem Biophys Res Comm by YM Kuo (1998)
  44. Merched A, Xia Y, Visvikis S, Serot JM, Siest G . Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 2000; 21: 27–30. (10.1016/S0197-4580(99)00103-7) / Neurobiol Aging by A Merched (2000)
  45. Kazi D, Farmer JA . Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary. Curr Atheroscler Rep 2005; 7: 88–94. (10.1007/s11883-005-0029-x) / Curr Atheroscler Rep by D Kazi (2005)
  46. Hayashi H, Kimura N, Yamaguchi H, Hasegawa K, Yokoseki T, Shibata M et al. A seed for Alzheimer amyloid in the brain. J Neurosci 2004; 24: 4894–4902. (10.1523/JNEUROSCI.0861-04.2004) / J Neurosci by H Hayashi (2004)
  47. Burns MP, Noble WJ, Olm V, Gaynor K, Casey E, LaFrancois J et al. Co-localization of cholesterol, apolipoprotein E and fibrillar abeta in amyloid plaques. Brain Res Mol Brain Res 2003; 100: 119–125. (10.1016/S0169-328X(02)00647-2) / Brain Res Mol Brain Res by MP Burns (2003)
  48. Bieschke J, Zhang Q, Powers ET, Lerner RA, Kelly JW . Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry 2005; 44: 4977–4983. (10.1021/bi0501030) / Biochemistry by J Bieschke (2005)
  49. Wolozin B, Brown J, Theisler C, Silberman S . The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease. CNS Drug Rev 2004; 10: 127–146. (10.1111/j.1527-3458.2004.tb00009.x) / CNS Drug Rev by B Wolozin (2004)
  50. Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 2002; 36: 27–32. (10.1016/S0022-3956(01)00050-4) / J Psychiatr Res by A Papassotiropoulos (2002)
  51. Schonknecht P, Lutjohann D, Pantel J, Bardenheuer H, Hartmann T, von Bergmann K et al. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett 2002; 32: 83–85. (10.1016/S0304-3940(02)00164-7) / Neurosci Lett by P Schonknecht (2002)
  52. Lutjohann D, Papassotiropoulos A, Bjorkhem I, Locatelli S, Bagli M, Oehring RD . Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 2000; 41: 195–198. (10.1016/S0022-2275(20)32052-6) / J Lipid Res by D Lutjohann (2000)
  53. Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli M, Jessen F, Rao ML et al. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. NeuroReport 2000; 11: 1959–1962. (10.1097/00001756-200006260-00030) / NeuroReport by A Papassotiropoulos (2000)
  54. Chalmers KA, Culpan D, Kehoe PG, Wilcock GK, Hughes A, Love S . Apo E promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's disease. NeuroReport 2004; 15: 95–98. (10.1097/00001756-200401190-00019) / NeuroReport by KA Chalmers (2004)
  55. Johansson A, Katzov H, Zetterberg H, Feuk L, Johansson B, Bogdanovic N et al. Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease. Hum Genet 2004; 114: 581–587. (10.1007/s00439-004-1107-9) / Hum Genet by A Johansson (2004)
  56. Desai P, DeKosky ST, Kamboh MI . Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease. Neurosci Lett 2002; 328: 9–12. (10.1016/S0304-3940(02)00443-3) / Neurosci Lett by P Desai (2002)
  57. Lutjohann D, Papassotiropoulos A, Bjorkhem I, Locatelli S, Bagli M, Oehring RD et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 2000; 41: 195–198. (10.1016/S0022-2275(20)32052-6) / J Lipid Res by D Lutjohann (2000)
  58. Dean M, Hamon Y, Chimini G . The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42: 1007–1017. (10.1016/S0022-2275(20)31588-1) / J Lipid Res by M Dean (2001)
  59. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001; 294: 1354–1357. (10.1126/science.294.5545.1354) / Science by DH Mauch (2001)
  60. Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski BA et al. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid β secretion. J Biol Chem 2003; 278: 13244–13256. (10.1074/jbc.M300044200) / J Biol Chem by RP Koldamova (2003)
  61. Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem 2004; 279: 40987–40993. (10.1074/jbc.M407963200) / J Biol Chem by SE Wahrle (2004)
  62. Wollmer MA, Streffer JR, Lutjohann D, Tsolaki M, Iakovidou V, Hegi T et al. ABCA 1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol Aging 2003; 24: 421–426. (10.1016/S0197-4580(02)00094-5) / Neurobiol Aging by MA Wollmer (2003)
  63. Sundqvist A, Ericsson J . Transcription-dependent degradation controls the stability of the SREBP family of transcription factors. Proc Natl Acad Sci USA 2003; 100: 13833–13838. (10.1073/pnas.2335135100) / Proc Natl Acad Sci USA by A Sundqvist (2003)
  64. Shimano H . Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res 2001; 40: 439–452. (10.1016/S0163-7827(01)00010-8) / Prog Lipid Res by H Shimano (2001)
  65. Spell C, Kolsch H, Lutjohann D, Kerksiek A, Hentschel F, Damian M et al. SREBP-1a polymorphism influences the risk of Alzheimer's disease in carriers of the apoE4 allele. Dement Geriatr Cogn Disord 2004; 18: 245–249. (10.1159/000080023) / Dement Geriatr Cogn Disord by C Spell (2004)
  66. Austen BM, Sidera C, Liu C, Frears E . The role of intracellular cholesterol on the processing of the β-amyloid precursor protein. J Nutr Health Aging 2003; 7: 31–36. / J Nutr Health Aging by BM Austen (2003)
  67. Ehehalt R, Keller P, Haass C, Thiele C, Simons K . Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 2003; 160: 113–123. (10.1083/jcb.200207113) / J Cell Biol by R Ehehalt (2003)
  68. Vetrivel KS, Cheng H, Lin W, Sakurai T, Li T, Nukina N et al. Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. J Biol Chem 2004; 279: 44945–44954. (10.1074/jbc.M407986200) / J Biol Chem by KS Vetrivel (2004)
  69. Bodovitz S, Klein WL . Cholesterol modulates alpha secretase cleavage of amyloid precursor protein. J Biol Chem 1996; 271: 4436–4440. (10.1074/jbc.271.8.4436) / J Biol Chem by S Bodovitz (1996)
  70. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K . Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998; 95: 6460–6464. (10.1073/pnas.95.11.6460) / Proc Natl Acad Sci USA by M Simons (1998)
  71. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F . Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc Natl Acad Sci USA 2001; 98: 5815–5820. (10.1073/pnas.081612998) / Proc Natl Acad Sci USA by E Kojro (2001)
  72. Wahrle S, Das P, Nyborg AC, Mclendon C, Shoji M, Kawarabayashi T et al. Cholesterol dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis 2002; 9: 11–23. (10.1006/nbdi.2001.0470) / Neurobiol Dis by S Wahrle (2002)
  73. Racchi M, Baetta R, Salvietti N, Ianna P, Franceschini G, Paoletti R et al. Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem J 1997; 322: 893–898. (10.1042/bj3220893) / Biochem J by M Racchi (1997)
  74. Galbete JL, Martin TR, Peressini E, Modena P, Bianchi R, Forloni G . Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem J 2000; 348: 307–313. (10.1042/bj3480307) / Biochem J by JL Galbete (2000)
  75. Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 2004; 167: 953–960. (10.1083/jcb.200404149) / J Cell Biol by J Abad-Rodriguez (2004)
  76. Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE et al. LDL receptor related protein, a multifunctional ApoE receptor binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995; 82: 331–340. (10.1016/0092-8674(95)90320-8) / Cell by MZ Kounnas (1995)
  77. Zerbinatti CV, Bu G . LRP and Alzheimer's disease. Rev Neurosci 2005; 16: 123–135. (10.1515/REVNEURO.2005.16.2.123) / Rev Neurosci by CV Zerbinatti (2005)
  78. von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM et al. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem 2005; 280: 17777–17785. (10.1074/jbc.M414248200) / J Biol Chem by CA von Arnim (2005)
  79. Lleo A, Waldron E, von Arnim CA, Herl L, Tangredi MM, Peltan ID et al. Low density lipoprotein receptor-related protein (LRP) interacts with presenilin 1 and is a competitive substrate of the amyloid precursor protein (APP) for gamma-secretase. J Biol Chem 2005; 280: 27303–27309. (10.1074/jbc.M413969200) / J Biol Chem by A Lleo (2005)
  80. Grimm MOW, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin. Nat Cell Biol 2005; 7: 1118–1123. (10.1038/ncb1313) / Nat Cell Biol by MOW Grimm (2005)
  81. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 2004; 101: 2070–2075. (10.1073/pnas.0305799101) / Proc Natl Acad Sci USA by RG Cutler (2004)
  82. Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson J-A . Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci USA 2002; 99: 13878–13883. (10.1073/pnas.172510899) / Proc Natl Acad Sci USA by L Wang (2002)
  83. Sun Y, Yao J, Kim TW, Tall AR . Expression of liver X receptor target genes decreases cellular amyloid β peptide secretion. J Biol Chem 2003; 278: 27688–27694. (10.1074/jbc.M300760200) / J Biol Chem by Y Sun (2003)
  84. Miyazaki A, Sakai M, Sakamoto Y, Horiuchi S . Acyl-coenzyme A: cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis. Curr Opin Investig Drugs 2003; 4: 1095–1099. / Curr Opin Investig Drugs by A Miyazaki (2003)
  85. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT et al. Acyl-coenzyme A:cholesterol acyltransferase modulates the generation of the amyloid β peptide. Nat Cell Biol 2001; 3: 905–912. (10.1038/ncb1001-905) / Nat Cell Biol by L Puglielli (2001)
  86. Puglielli L, Ellis BC, Ingano LA, Kovacs DM . Role of acyl-coenzyme A:cholesterol acyltransferase activity in the processing of the amyloid precursor protein. J Mol Neurosci 2004; 24: 93–96. (10.1385/JMN:24:1:093) / J Mol Neurosci by L Puglielli (2004)
  87. Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A et al. The ACAT inhibitor CP-113, 818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 2004; 44: 227–238. (10.1016/j.neuron.2004.08.043) / Neuron by B Hutter-Paier (2004)
  88. Wollmer MA, Streffer JR, Tsolaki M, Grimaldi LM, Lutjohann D, Thal D et al. Genetic association of acyl-conenzyme A:cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and the risk for Alzheimer's disease. Mol Psychiatry 2003; 8: 635–638. (10.1038/sj.mp.4001296) / Mol Psychiatry by MA Wollmer (2003)
  89. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA . Statins and the risk of dementia. Lancet 2000; 356: 1627–1631. (10.1016/S0140-6736(00)03155-X) / Lancet by H Jick (2000)
  90. Wolozin B, Kellman W, Rousseau P, Celesia GG, Siegel G . Decreased prevalence of Alzheimer's disease associated with 3-hydroxy3methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439–1443. (10.1001/archneur.57.10.1439) / Arch Neurol by B Wolozin (2000)
  91. Austen B, Christodoulou G, Terry JE . Relation between cholesterol levels, statins and Alzheimer's disease in the human population. J Nutr Health Aging 2002; 6: 377–382. / J Nutr Health Aging by B Austen (2002)
  92. Moghadasian MH . Clinical pharmacology of 3-hydroxy-3methylglutaryl coenyzme A reductase inhibitors. Life Sci 1999; 65: 1329–1337. (10.1016/S0024-3205(99)00199-X) / Life Sci by MH Moghadasian (1999)
  93. Park I-H, Hwang EM, Hong HS, Boo JH, Oh SS, Lee J et al. Lovastatin enhances Aβ production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging 2003; 24: 637–643. (10.1016/S0197-4580(02)00155-0) / Neurobiol Aging by I-H Park (2003)
  94. Petanceska SS, DeRosa S, Olm V, Diaz N, Sharma A, Thomas-Bryant T et al. Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci 2002; 19: 155–161. (10.1007/s12031-002-0026-2) / J Mol Neurosci by SS Petanceska (2002)
  95. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P et al. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 5856–5861. (10.1073/pnas.081620098) / Proc Natl Acad Sci USA by K Fassbender (2001)
  96. Hoglund K, Thelen KM, Syversen S, Sjogren M, von Bergmann K, Wallin A et al. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2005; 19: 256–265. (10.1159/000084550) / Dement Geriatr Cogn Disord by K Hoglund (2005)
  97. Ledesma MD, Dotti CG . The conflicting role of brain cholesterol in Alzheimer's disease: lessons from the brain plasminogen system. Biochem Soc Symp 2005; 72: 129–138. (10.1042/bss0720129) / Biochem Soc Symp by MD Ledesma (2005)
  98. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 2005; 57: 789–794. (10.1002/ana.20493) / Ann Neurol by A Ruitenberg (2005)
  99. Poirier J . Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging 2005; 26: 355–361. (10.1016/j.neurobiolaging.2004.09.003) / Neurobiol Aging by J Poirier (2005)
  100. Baum L, Chen L, Masliah E, Chan YS, Ng HK, Pang CP . Lipoprotein lipase mutations and Alzheimer's disease. Am J Med Genet 1999; 88: 136–139. (10.1002/(SICI)1096-8628(19990416)88:2<136::AID-AJMG8>3.0.CO;2-D) / Am J Med Genet by L Baum (1999)
  101. Verd JC, Peris C, Alegret M, Diaz C, Hernandez G, Vasquez M et al. Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits. Br J Pharmacol 1999; 127: 1479–1485. (10.1038/sj.bjp.0702668) / Br J Pharmacol by JC Verd (1999)
  102. Schoonjans K, Peinado-Onsurbe J, Fruchart JC, Tailleux A, Fievet C, Auwerx J . 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglycerides levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett 1999; 452: 160–164. (10.1016/S0014-5793(99)00632-8) / FEBS Lett by K Schoonjans (1999)
  103. Hendrie HC, Ogunniyi A, Hall KS, Baiyewu O, Unverzagt FW, Gureje O et al. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA 2001; 285: 739–747. (10.1001/jama.285.6.739) / JAMA by HC Hendrie (2001)
  104. Graves AB, Rajaram L, Bowen JD, McCormick WC, McCurry SM, Larson EB . Cognitive decline and Japanese culture in a cohort of older Japanese Americans in King County, WA: the Kane Project. J Gerontol B Psychol Sci Soc Sci 1999; 54: s154–s161. (10.1093/geronb/54B.3.S154) / J Gerontol B Psychol Sci Soc Sci by AB Graves (1999)
  105. Engelhart MJ, Geerlings MI, Ruitenberg A, Van Swieten JC, Hofman A, Witteman JC et al. Diet and risk of dementia: does fat matter? The Rotterdam Study. Neurology 2002; 59: 1915–1921. (10.1212/01.WNL.0000038345.77753.46) / Neurology by MJ Engelhart (2002)
  106. Wu CW, Liao PC, Lin C, Kuo CJ, Chen ST, Chen HI et al. Brain region dependent increases in β-amyloid and apolipoprotein E levels in hypercholesterolemic rabbits. J Neural Transm 2003; 110: 641–649. (10.1007/s00702-002-0809-1) / J Neural Transm by CW Wu (2003)
  107. Sparks DL, Martins RN, Martin T . Rationale for the AD cholesterol lowering treatment trial and sex related differences in β-amyloid accumulation in the brains of spontaneously hypercholesterolemic Watanabe rabbits. Ann NY Acad Sci 2002; 977: 356–366. (10.1111/j.1749-6632.2002.tb04838.x) / Ann NY Acad Sci by DL Sparks (2002)
  108. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000; 7: 321–331. (10.1006/nbdi.2000.0304) / Neurobiol Dis by LM Refolo (2000)
  109. Wang J, Ho L, Qin W, Rocher AB, Seror I, Humala N et al. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J 2005; 19: 659–661. / FASEB J by J Wang (2005)
  110. Lutjohann D, Stroick M, Bertsch T, Kuhl S, Lindenthal B, Thelen K et al. High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 2004; 69: 431–438. (10.1016/j.steroids.2004.03.012) / Steroids by D Lutjohann (2004)
  111. Greenwood C, Winocur G . Learning and memory impairment in rats fed a high saturated fat diet. Behav Neural Biol 1990; 53: 74–87. (10.1016/0163-1047(90)90831-P) / Behav Neural Biol by C Greenwood (1990)
  112. Greenwood C, Winocur G . Cognitive performance in rats fed high-fat diets: a specific effect of saturated fatty acid intake. Behav Neurosci 1996; 110: 451–459. (10.1037/0735-7044.110.3.451) / Behav Neurosci by C Greenwood (1996)
  113. Winocur G, Greenwood C . High fat diets impair conditional discrimination learning in rats. Psychobiology 1993; 22: 286–292. (10.3758/BF03327147) / Psychobiology by G Winocur (1993)
  114. Winocur G, Greenwood C . The effects of high fat diets and environmental influences on cognitive performance in rats. Behav Brain Res 1999; 101: 153–161. (10.1016/S0166-4328(98)00147-8) / Behav Brain Res by G Winocur (1999)
  115. Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB . Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord 2003; 27: 260–268. (10.1038/sj.ijo.802225) / Int J Obes Relat Metab Disord by MF Elias (2003)
  116. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I . An 18 year follow up of overweight and risk of Alzheimer disease. Arch Intern Med 2003; 163: 1524–1528. (10.1001/archinte.163.13.1524) / Arch Intern Med by D Gustafson (2003)
  117. Haan MN, Wallace R . Can dementia be prevented? Brain aging in a population-based context. Annu Rev Public Health 2004; 25: 1–24. (10.1146/annurev.publhealth.25.101802.122951) / Annu Rev Public Health by MN Haan (2004)
  118. Balakrishnan K, Verdile G, Mehta PD, Beilby J, Nolan D, Galvao DA et al. Plasma Aβ42 correlates positively with increased body fat in healthy individuals. J Alzheimer's Dis 2005; 8: 269–282. (10.3233/JAD-2005-8305) / J Alzheimer's Dis by K Balakrishnan (2005)
  119. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005; 62: 1556–1560. (10.1001/archneur.62.10.1556) / Arch Neurol by M Kivipelto (2005)
  120. Clandinin MT, Cheema S, Field CJ, Baracos VE . Dietary lipids influence insulin action. Ann NY Acad Sci 1993; 683: 151–163. (10.1111/j.1749-6632.1993.tb35701.x) / Ann NY Acad Sci by MT Clandinin (1993)
  121. Storlien LH, Kriketos AD, Jenkins AB, Baur LA, Pan DA, Tapsell LC et al. Does dietary fat influence insulin action? Ann NY Acad Sci 1997; 827: 287–301. (10.1111/j.1749-6632.1997.tb51842.x) / Ann NY Acad Sci by LH Storlien (1997)
  122. Berdanier CD . The BHE rat: an animal model for the study of non-insulin-dependent diabetes mellitus. FASEB J 1991; 5: 2139–2144. (10.1096/fasebj.5.8.2022312) / FASEB J by CD Berdanier (1991)
  123. Manco M, Calvani C, Mingrone G . Effects of dietary fatty acids on insulin sensitivity and secretion. Diabetes Obes metab 2004; 6: 402–413. (10.1111/j.1462-8902.2004.00356.x) / Diabetes Obes metab by M Manco (2004)
  124. Holness MJ, Greenwood GK, Smith ND, Sugden MC . Diabetogenic impact of long-chain omega-3 fatty acids on pancreatic beta-cell function and the regulation of endogenous glucose production. Endocrinology 2003; 144: 3958–3968. (10.1210/en.2003-0479) / Endocrinology by MJ Holness (2003)
  125. Marshall JA, Bessesen DH, Hamman RF . High saturated fat and low starch and fibre are associated with hyperinsulinaemia in a non-diabetic population: the San Louis Valley Diabetes Study. Diabetologia 1997; 40: 430–438. (10.1007/s001250050697) / Diabetologia by JA Marshall (1997)
  126. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM . Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996; 39: 1392–1397. (10.1007/s001250050588) / Diabetologia by A Ott (1996)
  127. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC . Increased risk of type 2 diabetes in Alzheimer's disease. Diabetes 2004; 53: 474–481. (10.2337/diabetes.53.2.474) / Diabetes by J Janson (2004)
  128. Bruce DG, Casey GP, Grange V, Clarnette RC, Almeida OP, Foster JK et al. Cognitive impairment, physical disability and depressive symptoms in older diabetic patients: the Fremantle cognition in diabetes study. Diabetes Res Clin Pract 2003; 61: 59–67. (10.1016/S0168-8227(03)00084-6) / Diabetes Res Clin Pract by DG Bruce (2003)
  129. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. Br Med J 1997; 315: 1045–1049. (10.1136/bmj.315.7115.1045) / Br Med J by J Kuusisto (1997)
  130. Stewart R, Liolitsa D . Type 2 diabetes, cognitive impairment and dementia. Diabet Med 1999; 16: 93–112. (10.1046/j.1464-5491.1999.00027.x) / Diabet Med by R Stewart (1999)
  131. MacKnight C, Rockwood K, Awalt E, McDowell I . Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 2002; 14: 77–83. (10.1159/000064928) / Dement Geriatr Cogn Disord by C MacKnight (2002)
  132. Hassing LB, Johansson B, Nilsson SE, Berg S, Pedersen NL, Gatz M et al. Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population based study of the oldest old. Int Psychogeriatr 2002; 14: 239–248. (10.1017/S104161020200844X) / Int Psychogeriatr by LB Hassing (2002)
  133. Martins IJ, Redgrave TG . Obesity and postprandial lipid metabolism. Feast or famine? J Nutr Biochem 2004; 15: 130–141. (10.1016/j.jnutbio.2003.10.006) / J Nutr Biochem by IJ Martins (2004)
  134. Pihlajamaki J, Gylling H, Miettinen TA, Laakso M . Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglycemic men. J Lipid Res 2004; 45: 507–512. (10.1194/jlr.M300368-JLR200) / J Lipid Res by J Pihlajamaki (2004)
  135. Simonen PP, Gylling HK, Miettinen TA . Diabetes contributes to cholesterol metabolism regardless of obesity. Diabetes Care 2002; 25: 1511–1515. (10.2337/diacare.25.9.1511) / Diabetes Care by PP Simonen (2002)
  136. Peila R, Rodriguez BL, Launer LJ . Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002; 51: 1256–1262. (10.2337/diabetes.51.4.1256) / Diabetes by R Peila (2002)
  137. Messier C . Diabetes, Alzheimer's disease and apolipoprotein genotype. Exp Gerontol 2003; 38: 941–946. (10.1016/S0531-5565(03)00153-0) / Exp Gerontol by C Messier (2003)
  138. Kuhl DE, Metter EJ, Riege WH . Patterns of cerebral glucose utilization in depression, multiple infarct dementia, and Alzheimer's Disease. In: Sokoloff L (ed). Brain Imaging and Brain Function. Raven Press: New York, 1985. / Brain Imaging and Brain Function by DE Kuhl (1985)
  139. Duara R, Grady C, Haxby J, Sundaram M, Cutler NR, Heston L et al. Positron emission tomography in Alzheimer's disease. Neurology 1986; 36: 879–887. (10.1212/WNL.36.7.879) / Neurology by R Duara (1986)
  140. Herholz K . PET studies in dementia. Ann Nucl Med 2003; 17: 79–89. (10.1007/BF02988444) / Ann Nucl Med by K Herholz (2003)
  141. Craft S, Zallen G, Baker LD . Glucose and memory in mild senile dementia of the Alzheimer type. J Clin Exp Neuropsychol 1992; 14: 253–267. (10.1080/01688639208402827) / J Clin Exp Neuropsychol by S Craft (1992)
  142. Bucht G, Adolfsson R, Lithner F, Winblad B . Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. Acta Med Scand 1983; 213: 387–392. (10.1111/j.0954-6820.1983.tb03756.x) / Acta Med Scand by G Bucht (1983)
  143. Fujisawa Y, Sasaki K, Akiyama K . Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol Psychiat 1991; 30: 1219–1228. (10.1016/0006-3223(91)90158-I) / Biol Psychiat by Y Fujisawa (1991)
  144. Kilander L, Boberg M, Lithell H . Peripheral glucose metabolism and insulin sensitivity in Alzheimer's disease. Acta Neurol Scand 1993; 87: 294–298. (10.1111/j.1600-0404.1993.tb05511.x) / Acta Neurol Scand by L Kilander (1993)
  145. Winograd CH, Jacobson DH, Minkoff JR, Peabody CA, Taylor BS, Widrow L et al. Blood glucose and insulin response in patients with senile dementia of the Alzheimer's type. Biol Psychiat 1991; 30: 507–511. (10.1016/0006-3223(91)90313-B) / Biol Psychiat by CH Winograd (1991)
  146. Sims NR, Finegan JM, Blass JP . Altered metabolic properties of cultured skin fibroblasts in Alzheimer's disease. Ann Neurol 1987; 21: 451–457. (10.1002/ana.410210507) / Ann Neurol by NR Sims (1987)
  147. Hoyer S . Brain glucose and energy metabolism abnormalities in sporadic Alzheimer's disease. Causes and consequences: an update. Exp Gerontol 2000; 35: 1363–1372. (10.1016/S0531-5565(00)00156-X) / Exp Gerontol by S Hoyer (2000)
  148. Craft S, Dagogo-Jack SE, Wiethop BV, Murphy C, Nevins RT, Fleischman S et al. Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci 1993; 207: 926–940. (10.1037/0735-7044.107.6.926) / Behav Neurosci by S Craft (1993)
  149. Manning CA, Ragozzino ME, Gold PE . Glucose enhancement of memory in patients with probable senile dementia of the Alzheimer's type. Neurobiol Aging 1993; 14: 523–528. (10.1016/0197-4580(93)90034-9) / Neurobiol Aging by CA Manning (1993)
  150. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D et al. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA 2005; 102: 8299–8302. (10.1073/pnas.0500579102) / Proc Natl Acad Sci USA by EM Reiman (2005)
  151. Boyt AA, Taddei TK, Hallmeyer J, Helmerhorst E, Gandy SE, Craft S et al. The effect of insulin and glucose on the plasma concentration of Alzheimer's amyloid precursor protein. Neuroscience 2000; 95: 727–734. (10.1016/S0306-4522(99)00458-3) / Neuroscience by AA Boyt (2000)
  152. Yamagishi S, Nakamura K, Inoue H, Kikuchi S, Takeuchi M . Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease. Med Hypotheses 2005; 64: 1205–1207. (10.1016/j.mehy.2005.01.016) / Med Hypotheses by S Yamagishi (2005)
  153. Zhao WQ, Alkon DL . Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 2001; 177: 125–134. (10.1016/S0303-7207(01)00455-5) / Mol Cell Endocrinol by WQ Zhao (2001)
  154. Edbauer D, Willem M, Lammich S, Steiner H, Haass C . Insulin-degrading enzyme rapidly removes the β-amyloid precursor protein intracellular domain (AICD). J Biol Chem 2002; 277: 13389–13393. (10.1074/jbc.M111571200) / J Biol Chem by D Edbauer (2002)
  155. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003; 100: 4162–4167. (10.1073/pnas.0230450100) / Proc Natl Acad Sci USA by W Farris (2003)
  156. Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ et al. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol 2005; 62: 1539–1544. (10.1001/archneur.62.10.noc50112) / Arch Neurol by MA Fishel (2005)
  157. Luchsinger JA, Tang MX, Shea S, Mayeux R . Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187–1192. (10.1212/01.WNL.0000140292.04932.87) / Neurology by JA Luchsinger (2004)
  158. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 2004; 18: 902–904. (10.1096/fj.03-0978fje) / FASEB J by L Ho (2004)
  159. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R . Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 2002; 22: RC221. (10.1523/JNEUROSCI.22-10-j0001.2002) / J Neurosci by L Xie (2002)
  160. Xie L, Martins RN, Racchi M, Craft S, Helmerhorst E . Beta amyloid antagonizes insulin promoted secretion of the amyloid precursor protein. J Alzheimer's Dis 2002; 4: 369–374. (10.3233/JAD-2002-4504) / J Alzheimer's Dis by L Xie (2002)
  161. Solano DC, Sironi M, Bonfini C, Solerte SB, Govoni S, Racchi M . Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J 2000; 14: 1015–1022. (10.1096/fasebj.14.7.1015) / FASEB J by DC Solano (2000)
  162. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P et al. Stimulation of β-amyloid precursor protein trafficking by insulin reduces intraneuronal β-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 2001; 21: 2561–2570. (10.1523/JNEUROSCI.21-08-02561.2001) / J Neurosci by L Gasparini (2001)
  163. Helbecque N, Abderrahamani A, Meylan L, Riederer B, Mooser V, Miklossy J et al. Islet-brain1/C-Jun N-terminal kinase interacting protein-1 (IB1/JIP-1) promoter variant is associated with Alzheimer's disease. Mol Psychiatry 2003; 8: 413–422. (10.1038/sj.mp.4001344) / Mol Psychiatry by N Helbecque (2003)
  164. Waeber G, Delplanque J, Bonny C, Mooser V, Steinmann M, Widmann C et al. The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes. Nat Genet 2000; 24: 291–295. (10.1038/73523) / Nat Genet by G Waeber (2000)
  165. De la Monte SM, Wands JR . Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimer's Dis 2005; 7: 45–61. (10.3233/JAD-2005-7106) / J Alzheimer's Dis by SM De la Monte (2005)
  166. Bondy CA, Cheng CM . Signaling by insulin-like growth factor 1 in brain. Eur J Pharmacol 2004; 490: 25–31. (10.1016/j.ejphar.2004.02.042) / Eur J Pharmacol by CA Bondy (2004)
  167. Dupont J, LeRoith D . Insulin and insulin-like growth factor I receptors: similarities and differences in signal transduction. Horm Res 2001; 55 (Suppl 2): 22–26. / Horm Res by J Dupont (2001)
  168. Dore S, Kar S, Rowe W, Quirion R . Distribution and levels of [125I]IGF-I, [125I]IGF-II and [125I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats. Neuroscience 1997; 80: 1033–1040. (10.1016/S0306-4522(97)00154-1) / Neuroscience by S Dore (1997)
  169. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes? J Alzheimer's Dis 2005; 7: 63–80. (10.3233/JAD-2005-7107) / J Alzheimer's Dis by E Steen (2005)
  170. Dore S, Kar S, Quirion R . Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity. Proc Natl Acad Sci USA 1997; 94: 4772–4777. (10.1073/pnas.94.9.4772) / Proc Natl Acad Sci USA by S Dore (1997)
  171. Zheng WH, Kar S, Dore S, Quirion R . Insulin-like growth factor-1 (IGF-1): a neuroprotective trophic factor acting via the Akt kinase pathway. J Neural Transm Supp 2000; 60: 261–272. / J Neural Transm Supp by WH Zheng (2000)
  172. Wei W, Wang X, Kusiak JW . Signaling events in amyloid β-peptide-induced neuronal death and insulin-like growth factor I protection. J Biol Chem 2002; 277: 17649–17656. (10.1074/jbc.M111704200) / J Biol Chem by W Wei (2002)
  173. Wallace WC, Akar CA, Lyons WE, Kole HK, Egan JM, Wolozin B . Amyloid precursor protein requires the insulin signaling pathway for neurotrophic activity. Brain Res Mol Brain Res 1997; 52: 213–227. (10.1016/S0169-328X(97)00259-3) / Brain Res Mol Brain Res by WC Wallace (1997)
  174. Rall SC, Weisgraber KH, Mahley RW . Human apolipoprotein E. The complete amino acid sequence. J Biol Chem 1982; 257: 4171–4178. (10.1016/S0021-9258(18)34702-1) / J Biol Chem by SC Rall (1982)
  175. Mahley RW . Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622–630. (10.1126/science.3283935) / Science by RW Mahley (1988)
  176. Martins RN, Clarnette R, Fisher C, Broe GA, Brooks WS, Montgomery P et al. Apo E genotypes in Australia: roles in early and late onset Alzheimer's disease and Down's syndrome. NeuroReport 1995; 6: 1513–1516. (10.1097/00001756-199507310-00012) / NeuroReport by RN Martins (1995)
  177. Zannis VI, Breslow JL, Utermann G, Mahley RW, Weisgraber KH, Havel RJ et al. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res 1982; 23: 911–914. (10.1016/S0022-2275(20)38094-9) / J Lipid Res by VI Zannis (1982)
  178. Kamboh MI, Sepehrnia B, Ferrell RE . Genetic studies of human apolipoproteins. VI. Common polymorphism of apolipoprotein E in blacks. Dis Markers 1989; 7: 49–55. / Dis Markers by MI Kamboh (1989)
  179. Gelernter J, Kranzler H, Lacobelle J . Population studies of polymorphisms at loci of neuropsychiatric interest (tryptophan hydroxylase (TPH), dopamine transporter protein (SLC6A3), D3 dopamine receptor (DRD3), apolipoprotein E (APOE), mu opioid receptor (OPRM1), and ciliary neurotrophic factor (CNTF)). Genomics 1998; 52: 289–297. (10.1006/geno.1998.5454) / Genomics by J Gelernter (1998)
  180. Tsukamoto K, Watanabe T, Matsushima T, Kinoshita M, Kato H, Hashimoto Y et al. Determination by PCR-RFLP of apo E genotype in a Japanese population. J Lab Clin Med 1993; 121: 598–602. / J Lab Clin Med by K Tsukamoto (1993)
  181. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC . Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002; 155: 487–495. (10.1093/aje/155.6.487) / Am J Epidemiol by JE Eichner (2002)
  182. Roheim PS, Carey M, Forte T, Vega GL . Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci USA 1979; 76: 4646–4649. (10.1073/pnas.76.9.4646) / Proc Natl Acad Sci USA by PS Roheim (1979)
  183. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH . Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E(LDL) receptors in the brain. J Biol Chem 1987; 262: 14352–14360. (10.1016/S0021-9258(18)47945-8) / J Biol Chem by RE Pitas (1987)
  184. Holtzman DM, Pitas RE, Kilbridge J, Nathan B, Mahley RW, Bu G et al. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc Natl Acad Sci USA 1995; 92: 9480–9484. (10.1073/pnas.92.21.9480) / Proc Natl Acad Sci USA by DM Holtzman (1995)
  185. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW . Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 1987; 917: 148–161. (10.1016/0005-2760(87)90295-5) / Biochim Biophys Acta by RE Pitas (1987)
  186. Willnow TE . The low density lipoprotein receptor gene family: multiple roles in lipid metabolism. J Mol Med 1999; 77: 306–315. (10.1007/s001090050356) / J Mol Med by TE Willnow (1999)
  187. Vance JE, Hayashi H, Karten B . Cholesterol homeostasis in neurons and glial cells. Semin Cell Dev Biol 2005; 16: 193–212. (10.1016/j.semcdb.2005.01.005) / Semin Cell Dev Biol by JE Vance (2005)
  188. Oner P, Bekpinar S, Oz B . Alterations in some lipid components and Ca2+ ATPase activity in brains of rats fed an atherogenic diet. Res Commun Chem Pathol Pharmacol 1991; 72: 337–345. / Res Commun Chem Pathol Pharmacol by P Oner (1991)
  189. Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R . A new function for the LDL receptor: transcytosis of LDL across the blood–brain barrier. J Cell Biol 1997; 138: 877–889. (10.1083/jcb.138.4.877) / J Cell Biol by B Dehouck (1997)
  190. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90: 1977–1981. (10.1073/pnas.90.5.1977) / Proc Natl Acad Sci USA by WJ Strittmatter (1993)
  191. Schellenberg GD . Genetic dissection of Alzheimer's disease, a heterogeneous disorder. Proc Natl Acad Sci USA 1995; 92: 8552–8559. (10.1073/pnas.92.19.8552) / Proc Natl Acad Sci USA by GD Schellenberg (1995)
  192. Osuntokun BO, Sahota A, Ogunniyi AO, Gureje O, Baiyewu O, Adeyinka A et al. Lack of association between apolipoprotein E epsilon 4 and Alzheimer's disease in elderly Nigerians. Ann Neurol 1995; 38: 463–465. (10.1002/ana.410380319) / Ann Neurol by BO Osuntokun (1995)
  193. Hendrie HC, Ogunniyi A, Hall KS, Baiyewu O, Unverzagt FW, Gureje O et al. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA 2001; 285: 739–747. (10.1001/jama.285.6.739) / JAMA by HC Hendrie (2001)
  194. Smith MA, Petot GJ, Perry G . Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer's disease. J Alzheimer Dis 1999; 1: 203–206. (10.3233/JAD-1999-14-502) / J Alzheimer Dis by MA Smith (1999)
  195. Petot GJ, Traore F, Debanne SM, Lerner AJ, Smyth KA, Friedland RP . Interactions of apolipoprotein E genotype and dietary fat intake of healthy older persons during mid-adult life. Metabolism 2003; 52: 279–281. (10.1053/meta.2003.50066) / Metabolism by GJ Petot (2003)
  196. Mulder M, Jansen JP, Janssen BJ, van de Berg WD, van der Boom H, Havekes LM et al. Low density lipoprotein receptor knockout mice display impaired spatial memory associated with a decreased synaptic density in the hippocampus. Neurobiol Dis 2004; 16: 212–219. (10.1016/j.nbd.2004.01.015) / Neurobiol Dis by M Mulder (2004)
  197. Gordon I, Genis I, Grauer E, Sehayek E, Michaelson DM . Biochemical and cognitive studies of apolipoprotein E deficient mice. Mol Chem Neuropathol 1996; 1: 97–103. (10.1007/BF02815210) / Mol Chem Neuropathol by I Gordon (1996)
  198. Levi O, Jongen-Relo AL, Feldon J, Michaelson DM . Brain area- and isoform-specific inhibition of synaptic plasticity by apoE4. J Neurol Sci 2005; 229–230: 241–248. (10.1016/j.jns.2004.11.035) / J Neurol Sci by O Levi (2005)
  199. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE . Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994; 264: 850–852. (10.1126/science.8171342) / Science by BP Nathan (1994)
  200. Scott BL, Welch K, deSerrano V, Moss NC, Roses AD, Strittmatter WJ . Human apolipoprotein E accelerates microtubule polymerization in vitro. Neurosci Lett 1998; 245: 105–108. (10.1016/S0304-3940(98)00180-3) / Neurosci Lett by BL Scott (1998)
  201. Nathan BP, Chang KC, Bellosta S, Brisch E, Ge N, Mahley RW et al. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J Biol Chem 1995; 270: 19791–19799. (10.1074/jbc.270.34.19791) / J Biol Chem by BP Nathan (1995)
  202. Sun Y, Wu S, Bu G, Onifade MK, Patel SN, LaDu MJ et al. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci 1998; 18: 3261–3272. (10.1523/JNEUROSCI.18-09-03261.1998) / J Neurosci by Y Sun (1998)
  203. Poirier J, Hess M, May PC, Finch CE . Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Brain Res Mol Brain Res 1991; 11: 97–106. (10.1016/0169-328X(91)90111-A) / Brain Res Mol Brain Res by J Poirier (1991)
  204. Morris JC . The challenge of characterizing normal brain aging in relation to Alzheimer's disease. Neurobiol Aging 1997; 18: 388–389. (10.1016/S0197-4580(97)00055-9) / Neurobiol Aging by JC Morris (1997)
  205. Poirier J, Baccichet A, Dea D, Gauthier S . Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience 1993; 55: 81–90. (10.1016/0306-4522(93)90456-P) / Neuroscience by J Poirier (1993)
  206. Irizarry MC, Deng A, Lleo A, Berezovska O, Von Arnim CA, Martin-Rehrmann M et al. Apolipoprotein E modulates γ-secretase cleavage of the amyloid precursor protein. J Neurochem 2004; 90: 1132–1143. (10.1111/j.1471-4159.2004.02581.x) / J Neurochem by MC Irizarry (2004)
  207. Hass S, Fresser F, Kochl S, Beyreuther K, Utermann G, Baier G . Physical interaction of apo E with amyloid precursor protein independent of the amyloid abeta region in vitro. J Biol Chem 2001; 273: 13892–13897. / J Biol Chem by S Hass (2001)
  208. Hass S, Weidemann A, Utermann G, Baier G . Intracellular apolipoprotein E affects amyloid precursor protein processing and amyloid abeta production in COS-1 cells. Mol Genet Genomics 2001; 265: 791–800. (10.1007/s004380100473) / Mol Genet Genomics by S Hass (2001)
  209. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K . Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991; 541: 163–166. (10.1016/0006-8993(91)91092-F) / Brain Res by Y Namba (1991)
  210. Wisniewski T, Frangione B . Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992; 135: 235–238. (10.1016/0304-3940(92)90444-C) / Neurosci Lett by T Wisniewski (1992)
  211. Naslund J, Thyberg J, Tjernberg LO, Wernstedt C, Karlstrom AR, Bogdanovic N et al. Characterization of stable complexes involving apo E and amyloid beta peptide in Alzheimer's disease brain. Neuron 1995; 15: 219–228. (10.1016/0896-6273(95)90079-9) / Neuron by J Naslund (1995)
  212. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 9649–9653. (10.1073/pnas.90.20.9649) / Proc Natl Acad Sci USA by DE Schmechel (1993)
  213. Gearing M, Mori H, Mirra SS . Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol 1996; 39: 395–399. (10.1002/ana.410390320) / Ann Neurol by M Gearing (1996)
  214. Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C et al. Fibrillogenesis in Alzheimer's disease of amyloid β peptides and apolipoprotein E. Biochem J 1995; 306: 599–604. (10.1042/bj3060599) / Biochem J by EM Castano (1995)
  215. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M . Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform specific effects and implications for late onset Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90: 8098–8102. (10.1073/pnas.90.17.8098) / Proc Natl Acad Sci USA by WJ Strittmatter (1993)
  216. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A et al. Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel fibrils. J Clin Invest 1994; 94: 860–869. (10.1172/JCI117407) / J Clin Invest by DA Sanan (1994)
  217. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE . Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem 1994; 269: 23403–23406. (10.1016/S0021-9258(17)31529-6) / J Biol Chem by MJ LaDu (1994)
  218. LaDu MJ, Pederson TM, Frail DE, Reardon CA, Getz GS, Falduto MT . Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J Biol Chem 1995; 270: 9039–9042. (10.1074/jbc.270.16.9039) / J Biol Chem by MJ LaDu (1995)
  219. Yang DS, Smith JD, Zhou Z, Gandy SE, Martins RN . Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J Neurochem 1997; 68: 721–725. (10.1046/j.1471-4159.1997.68020721.x) / J Neurochem by DS Yang (1997)
  220. Zhou Z, Smith JD, Greengard P, Gandy SE . Alzheimer amyloid-β peptide forms denaturant-resistant complex with Type å3 but not å4 isoform of native apolipoprotein E. Mol Med 1996; 2: 175–180. (10.1007/BF03401614) / Mol Med by Z Zhou (1996)
  221. Jordan J, Galindo MF, Miller RJ, Reardon CA, Getz GS, LaDu MJ . Isoform-specific effect of apolipoprotein E on cell survival and β-amyloid induced toxicity in rat hippocampal pyramidal neuronal cultures. J Neurosci 1998; 18: 195–204. (10.1523/JNEUROSCI.18-01-00195.1998) / J Neurosci by J Jordan (1998)
  222. Yang DS, Small DH, Seydel U, Smith JD, Hallmayer J, Gandy SE et al. Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience 1999; 90: 1217–1226. (10.1016/S0306-4522(98)00561-2) / Neuroscience by DS Yang (1999)
  223. Manelli AM, Stine WB, Van Eldick LJ, LaDu MJ . ApoE and Abeta1–42 interactions: effects of isoform and conformation on structure and function. J Mol Neurosci 2004; 23: 235–246. (10.1385/JMN:23:3:235) / J Mol Neurosci by AM Manelli (2004)
  224. Hone E, Martins IJ, Jeoung M, Ji TH, Gandy S, Martins RN . Alzheimer's disease Aβ peptide modulates apoE isoform specific effects on receptor binding. J Alzheimers Dis 2005; 7: 303–314. (10.3233/JAD-2005-7406) / J Alzheimers Dis by E Hone (2005)
  225. Hone E, Martins IJ, Fonte J, Martins RN . Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J Alzheimer's Dis 2003; 5: 1–8. (10.3233/JAD-2003-5101) / J Alzheimer's Dis by E Hone (2003)
  226. Winkler K, Scharnagl H, Tisljar U, Hoschutzky H, Friedrich I, Hoffmann MM . Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis. J Lipid Res 1999; 40: 447–455. (10.1016/S0022-2275(20)32449-4) / J Lipid Res by K Winkler (1999)
  227. Zlokovic BV . Clearing amyloid through the blood brain barrier. J Neurochem 2004; 89: 807–814. (10.1111/j.1471-4159.2004.02385.x) / J Neurochem by BV Zlokovic (2004)
  228. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB et al. P-glycoprotein deficiency at the blood–brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J Clin Invest 2005; 115: 3285–3290. (10.1172/JCI25247) / J Clin Invest by JR Cirrito (2005)
  229. Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R et al. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med 2005; 11: 959–965. (10.1038/nm1287) / Nat Med by Z Wu (2005)
  230. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000; 97: 2892–2897. (10.1073/pnas.050004797) / Proc Natl Acad Sci USA by DM Holtzman (2000)
  231. Han X, Fagan AM, Cheng H, Morris JC, Xiong C, Holtzman DM . Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol 2003; 54: 115–119. (10.1002/ana.10618) / Ann Neurol by X Han (2003)
  232. Han X, Cheng H, Fryer JD, Fagan AM, Holtzman DM . Novel role for apolipoprotein E in the central nervous system. J Biol Chem 2003; 278: 8043–8051. (10.1074/jbc.M212340200) / J Biol Chem by X Han (2003)
  233. Mattson MP . Neuroprotective signaling and the aging brain: take away my food and let me run. Brain Res 2000; 886: 47–53. (10.1016/S0006-8993(00)02790-6) / Brain Res by MP Mattson (2000)
  234. Brinton RD . A women's health issue: Alzheimer's disease and strategies for maintaining cognitive health. Int J Fertil Womens Med 1999; 44: 174–185. / Int J Fertil Womens Med by RD Brinton (1999)
  235. Grant WB, Campbell A, Itzhaki RF, Savory J . The significance of environmental factors in the etiology of Alzheimer's disease. J Alzheimer's Dis 2002; 4: 179–189. (10.3233/JAD-2002-4308) / J Alzheimer's Dis by WB Grant (2002)
  236. Solfrizzi V, Panza F, Capurso A . The role of diet in cognitive decline. J Neural Transm 2003; 110: 95–110. (10.1007/s00702-002-0766-8) / J Neural Transm by V Solfrizzi (2003)
Dates
Type When
Created 19 years, 2 months ago (June 20, 2006, 7:18 a.m.)
Deposited 3 years, 4 months ago (March 31, 2022, 11:27 p.m.)
Indexed 46 minutes ago (Aug. 27, 2025, 8:18 a.m.)
Issued 19 years, 2 months ago (June 20, 2006)
Published 19 years, 2 months ago (June 20, 2006)
Published Online 19 years, 2 months ago (June 20, 2006)
Published Print 19 years ago (Aug. 1, 2006)
Funders 0

None

@article{Martins_2006, title={Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s disease and cardiovascular disease}, volume={11}, ISSN={1476-5578}, url={http://dx.doi.org/10.1038/sj.mp.4001854}, DOI={10.1038/sj.mp.4001854}, number={8}, journal={Molecular Psychiatry}, publisher={Springer Science and Business Media LLC}, author={Martins, I J and Hone, E and Foster, J K and Sünram-Lea, S I and Gnjec, A and Fuller, S J and Nolan, D and Gandy, S E and Martins, R N}, year={2006}, month=jun, pages={721–736} }